| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (NCT05278364) | Shouyao Holdings (Beijing) Co. LTD | 2021-04-23 |
| Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis (NCT04760171) | The Leeds Teaching Hospitals NHS Trust | 2021-02-01 |
| Thermal Ablation of Cervical Metastases From Thyroid Carcinoma (NCT04522570) | Instituto do Cancer do Estado de São Paulo | 2020-12-14 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (NCT04280081) | Eli Lilly and Company | 2020-03-16 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (NCT04211337) | Loxo Oncology, Inc. | 2020-02-11 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations (NCT04161391) | Turning Point Therapeutics, Inc. | 2019-12-06 |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (NCT03838692) | Antonio Fojo | 2019-07-26 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (NCT03899792) | Eli Lilly and Company | 2019-06-13 |
| Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin (NCT02856347) | Institut Claudius Regaud | 2017-03-22 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889) | AbbVie | 2016-09-23 |
| Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients (NCT02465424) | Velindre NHS Trust | 2015-12-01 |
| A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (NCT01896479) | Exelixis | 2015-02-25 |
| Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer (NCT02363647) | Icahn School of Medicine at Mount Sinai | 2015-01-01 |
| 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer (NCT03643055) | University Medical Centre Ljubljana | 2014-09-03 |
| Radiolabeled Molecules for Medullary Thyroid Cancer (NCT01915485) | Instituto Nacional de Cancer, Brazil | 2013-08-01 |
| The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer (NCT01739634) | Salient Pharmaceuticals Incorporated | 2012-11-01 |
| Natural History Study of Children and Adults With Medullary Thyroid Cancer (NCT01660984) | National Cancer Institute (NCI) | 2012-07-30 |
| Vandetanib Risk Minimisation Effectiveness (NCT01757470) | Genzyme, a Sanofi Company | 2012-06-01 |
| Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib (NCT01539655) | Sanofi | 2012-02-01 |
| SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer (NCT01625520) | Federico II University | 2012-02-01 |
| Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (NCT01298323) | Sanofi | 2011-02-25 |
| An Initial Study of Lithium in Patients With Medullary Thyroid Cancer (NCT00582712) | University of Wisconsin, Madison | 2008-01-01 |
| Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma? (NCT06243965) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1997-01-01 |
| Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC (NCT04204928) | Blueprint Medicines Corporation | |
| Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (NCT03906331) | Eli Lilly and Company | |
| 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) (NCT02174679) | Jonsson Comprehensive Cancer Center | |